Bladder Cancer Surgery

(Source: HemOncToday.com) Source: MedWorm: Bladder Cancer

Abstract  A 74-year-old female was referred to our hospital for non-muscle invasive bladder tumors initially treated at another hospital.
Preoperatively, computed tomography and magnetic resonance imaging demonstrated non-muscle invasive bladder tumors and a vaginal
tumor. A second transurethral resection of the bladder tumors, transvaginal tumor resection, and systemic chemotherapy were
performed. The histopathological appearances of both tumors were very similar and the diagnoses were urothelial carcinoma
(UC). The pathogenesis of the vaginal UC was considered to be the primary UC or metastasis from the bladder UC. Vaginal UC
is extremely rare and this is only the 15th report in the literature.

Content Type Journal ArticleCategory Case ReportDOI 10.1007/s10147-010-009… Source: MedWorm: Bladder Cancer

IntroductionWhile adjuvant immunotherapy with Bacille Calmette Guerin (BCG) is effective in non-muscle-invasive bladder cancer (BC), adverse events (AEs) are considerable. Monocyte-derived activated killer cells (MAK) are discussed as essential in antitumoural immunoresponse, but their application may imply risks. The present trial compared autologous intravesical macrophage cell therapy (BEXIDEM(R)) to BCG in patients after transurethral resection (TURB) of BC.Material and Methods:This open-label trial included 137 eligible patients with TaG1-3, T1G1-2 plurifocal or unifocal tumours and [greater than or equal to] 2 occurrences within 24 months and was conducted from June 2004 to March 2007. Median follow-up for patients without recurrence was 12 months. Patients were randomized to BCG or …

Source: MedWorm: Bladder Cancer

Authors: Kassouf W, Kamat AM, Zlotta A, Bochner BH, Moore R, So A, Izawa J, Rendon RA, Lacombe L, Aprikian AG

PMID: 20514279 [PubMed - in process] (Source: Canadian Urological Association Journal) Source: MedWorm: Bladder Cancer

A single pre-operative intravesical electromotive (EMDA) instillation of mitomycin-C (MMC) improves a patient’s risk of non-muscle invasive bladder cancer (NMIBC) recurrence more than a single post-operative intravesical passive instillation, according to new research from investigators in Italy. This preventive measure can also enhance a patient’s disease-free interval. These data was presented during the 105th Annual Meeting of the American Urological Association (AUA)… (Source: Health News from Medical News Today)

Source: MedWorm: Bladder Cancer

(Source: International Journal of Urology)

Source: MedWorm: Bladder Cancer

Understanding those factors associated with the rising cost of bladder cancer care may inform guidelines dedicated to defining the best bladder cancer practices. In the care of noninvasive bladder cancer patients, we have yet to define the services that are being underutilized or overutilized. (Source: Cancer) Source: MedWorm: Bladder Cancer

Jain Abhishek, Goel Apul, Sankhwar S NIndian Journal of Urology 2010 26(1):153-155 (Source: Indian Journal of Urology)

Source: MedWorm: Bladder Cancer

Conclusions  The nomograms that have been developed can be used to predict the probability of recurrence and progression of nonmuscle invasive
bladder cancer.

Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10147-010-0049-6Authors
Toru Yamada, Gifu Urothelial Cancer Research Group Gifu JapanKunihiro Tsuchiya, Gifu Urothelial Cancer Research Group Gifu JapanSeiichi Kato, Gifu Urothelial Cancer Research Group Gifu JapanShingo Kamei, Gifu Urothelial Cancer Research Group Gifu JapanMitsuhiro Taniguchi, Gifu Urothelial Cancer Research Group Gifu JapanToshimi Takeuchi, Gifu Municipal Hospital Department of Urology Gifu JapanNaoki Yamamoto, Gifu University School of Medicine Department of Urology Gifu JapanHidetoshi Ehara, Gifu University School of Medicine… Source: MedWorm: Bladder Cancer